Make an Inquiry
Accelerating Liver Injury Drug Development

Injury to the liver remains a significant therapeutic challenge, with limited treatment options and a high burden on global health. Ace Therapeutics is a specialized partner in preclinical drug development, dedicated exclusively to advancing innovative therapies for liver injury and related disorders. Ace Therapeutics delivers comprehensive preclinical solutions spanning target validation, lead optimization, and IND-enabling studies, ensuring a seamless transition from early discovery to clinical readiness. Our scientific team brings deep expertise in liver biology and injury mechanisms, supported by advanced in vitro and in vivo platforms tailored to model complex hepatic pathologies. Rigorous adherence to regulatory standards underpins every stage of our process, providing robust and reproducible data that meet the expectations of global health authorities. With a focus on scientific rigor and technological innovation, Ace Therapeutics is committed to accelerating the development of transformative therapeutics for liver injury. We partner with biopharmaceutical innovators to drive efficient, high-quality drug candidates toward clinical success.

What is Liver InjuryTargets for Liver InjuryDrug Discovery and Development ServicesWhy Choose Us

What is Liver Injury

Liver injury, or hepatic injury, refers to a spectrum of conditions in which liver cells are damaged by various insults, including drugs, toxins, infections, ischemia, autoimmune reactions, and metabolic disturbances. The liver’s central role in metabolism, detoxification, and protein synthesis makes it vulnerable to these injuries. Pathophysiologically, liver injury arises from mechanisms such as direct cellular toxicity, immune-mediated responses, oxidative stress, and mitochondrial dysfunction, leading to hepatocyte apoptosis or necrosis. Types of liver injury include drug-induced liver injury (notably from acetaminophen), ischemic hepatitis, viral hepatitis, autoimmune hepatitis, and alcoholic liver injury, each with distinct etiologies and risk factors. Clinically, liver injury may present with asymptomatic elevations in liver enzymes, jaundice, fatigue, right upper quadrant pain, or, in severe cases, acute liver failure. Diagnosis involves a combination of clinical assessment, laboratory tests (including aminotransferases, bilirubin, and coagulation studies), serologic markers, imaging, and occasionally liver biopsy. Identifying the underlying cause is crucial for management. Treatment is etiology-specific; for example, acetylcysteine is the mainstay for acetaminophen-induced liver injury, acting as a glutathione precursor to mitigate toxicity. Supportive care, withdrawal of offending agents, and management of complications are central, with early intervention improving outcomes and reducing the risk of chronic sequelae.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-616-91-1-acetylcysteine-rec-inn-usan-bann-acetyl-l-cysteine acetylcysteine (Rec INN; USAN; BAN); N-acetyl-L-cysteine (JAN); N-acetylcysteine 616-91-1 C5 H9 N O3 S 163.195

Learn More

Targets for Liver Injury

Targets in Clinical or Later Phases of Development

Target Name
Nuclear factor kappa-light-chain-enhancer of activated B cells

Liver injury involves a complex interplay of inflammatory mediators, signaling molecules, and regulators of oxidative stress, cell death, and tissue remodeling. Key therapeutic targets include chemokines such as CCL5 and CX3CL1, which orchestrate immune cell recruitment and amplify hepatic inflammation, and cytokines like IL1B, which drive inflammatory cascades and promote hepatocyte apoptosis. Central signaling molecules—JAK1, JAK2, and MAP3K5—mediate the transduction of inflammatory and stress signals, while transcriptional coactivators CREBBP and EP300 regulate gene expression in response to injury. The NFE2L2/KEAP1 axis is pivotal for antioxidant defense, protecting hepatocytes from oxidative damage. Enzymes such as HDAC6 modulate epigenetic responses, and lipid signaling proteins like ENPP2 and PANX1 contribute to fibrosis and cell death, further exacerbating liver damage. These targets offer multiple avenues for therapeutic intervention in both acute and chronic liver injury. Small-molecule inhibitors and biologics targeting chemokine receptors (e.g., CCR5 antagonists for CCL5), JAK kinases (e.g., baricitinib), and MAP3K5 (e.g., selonsertib) are in various stages of preclinical and clinical development. NRF2 activators and KEAP1 inhibitors are being explored to enhance antioxidant responses, while HDAC6 and ENPP2 inhibitors show promise in reducing fibrosis and inflammation in animal models. Several of these targets, such as IL1B and JAK kinases, are validated biomarkers and therapeutic targets, supporting a precision medicine approach to stratify patients and tailor interventions for optimal outcomes in liver injury.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services

Our In Vitro Efficacy Testing Service for liver injury accelerates drug discovery by providing comprehensive screening and characterization of candidate therapies. Utilizing advanced cell-based, enzymatic, and molecular assays, we evaluate hepatocyte viability, function, and injury responses. Key methodologies include ATP, chemiluminescent, fluorescent, radioactivity, flow cytometry, and luciferase assays. We assess critical targets and pathways such as cytochrome P450, oxidative stress, and apoptosis. Quantitative parameters like EC-50, IC-50, Kd, MEC, and MIC support precise potency and efficacy profiling, enabling informed lead optimization and risk assessment to advance safer, more effective liver injury therapeutics.

Cdc Like Kinase 1 Cdc Like Kinase 2
E1A Binding Protein P300 Histone Deacetylase 6
Interleukin 1 Beta Janus Kinase 1
Janus Kinase 2 Kelch Like Ech Associated Protein 1
Mitogen-Activated Protein Kinase Kinase Kinase 5 Nfe2 Like Bzip Transcription Factor 2
Nuclear Receptor Subfamily 1 Group H Member 4 Pannexin 1

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the field of Injury, liver therapeutics through our specialized expertise and unwavering commitment to excellence. Our team consists of highly trained professionals with deep experience in Injury, liver research and drug development, ensuring that every project benefits from the latest scientific insights and best practices. We utilize advanced technology platforms that enable precise and efficient preclinical studies, providing our partners with reliable and actionable data. Ace Therapeutics has established a strong track record in delivering successful preclinical drug development services, earning the trust of clients who rely on our proven reliability and professionalism. We maintain rigorous quality standards and adhere strictly to regulatory requirements, ensuring that our work meets the highest benchmarks for safety and efficacy. Above all, Ace Therapeutics is driven by a passion to make a meaningful impact in the treatment of Injury, liver conditions, and we are committed to supporting our clients in bringing innovative therapeutics to patients in need. Choose Ace Therapeutics for your preclinical development needs and experience a partnership grounded in expertise, integrity, and a shared vision for better health outcomes.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for liver injury?

A: Preclinical research for liver injury drugs faces several unique challenges, including the complexity of liver physiology, the diversity of injury mechanisms (e.g., ischemic, toxic, immune-mediated), and the need for translational animal models that accurately mimic human pathophysiology. Our company addresses these challenges by utilizing a wide array of validated in vitro and in vivo models, including primary hepatocyte cultures and established rodent models of acute and chronic liver injury, to ensure robust and predictive preclinical data.

Q: What are the key regulatory considerations when developing drugs for liver injury?

A: Regulatory agencies such as the FDA and EMA require comprehensive data on safety, efficacy, and mechanism of action for liver injury drugs. This includes detailed toxicology studies, pharmacokinetics, and demonstration of efficacy in relevant animal models. Our team is experienced in designing preclinical programs that align with regulatory expectations, including guidance on IND-enabling studies, GLP compliance, and preparation of regulatory submissions to facilitate a smooth transition to clinical development.

Q: What technical aspects should be considered in liver injury preclinical research?

A: Technical considerations in liver injury research include the selection of appropriate models (e.g., CCl4-induced fibrosis, acetaminophen-induced hepatotoxicity), the use of advanced biomarkers for liver function and injury (such as ALT, AST, and novel molecular markers), and the application of imaging and histopathological techniques for comprehensive assessment. Our company offers integrated technical solutions, from model selection to biomarker analysis and imaging, ensuring high-quality, reproducible data.

Q: What is the typical timeline and cost for preclinical development of a liver injury drug candidate?

A: The preclinical development phase for a liver injury drug candidate typically spans 12-24 months, depending on the complexity of the required studies and regulatory requirements. Costs can vary widely, generally ranging from $1 million to $5 million, factoring in efficacy, safety, pharmacokinetics, and toxicology studies. We provide tailored project management and transparent budgeting to optimize timelines and control costs while maintaining the highest scientific and regulatory standards.

Q: What are the main success factors in preclinical liver injury drug development?

A: Key success factors include the use of predictive and clinically relevant animal models, early identification of pharmacodynamic and safety biomarkers, rigorous study design, and alignment with regulatory expectations. Our expertise in liver biology, model development, and regulatory strategy enables clients to de-risk their drug candidates and maximize the likelihood of successful progression to clinical trials.

Make an Inquiry